What Предуктал Treats: Main Uses and Benefits

Предуктал (Trimetazidine) is commonly used to provide symptomatic support for adult patients experiencing stable angina pectoris. The medication is applied as appropriate as an add-on therapy for patients whose symptoms may be inadequately managed by or who are intolerant to first-line antianginal therapies. The therapeutic domains may include chronic exertional chest pain, functional capacity limitations, and symptom persistence despite standard care.

This medication is used for managing the symptoms related to physical discomfort and noticeable physiological strain characteristic of stable angina, a condition where symptoms may intensify temporarily due to effort. The treatment helps reduce the frequency and intensity of these recurring episodes, contributing to easing the overall symptom burden. For patients, this supportive role may assist with managing symptoms that require short-term symptomatic assistance.

As an adjunctive support, the medication is relevant for easing symptoms that interfere with daily functioning and restrict physical activity. The therapeutic benefit may assist with maintaining functional stability, supporting a patient’s ability to handle exertion and supports general well-being during symptomatic phases.

---

Quick Fact: Relief for Exertional Discomfort This treatment is commonly used to help manage symptoms associated with stable angina pectoris, particularly when physical activity leads to predictable chest discomfort, offering support that contributes to easing the overall symptom load.

Regulatory References

1. Summary of Product Characteristics – Health Products Regulatory Authority (HPRA)

Предуктал (Trimetazidine) is a medication used in adult patients as add-on therapy for the symptomatic treatment of stable angina pectoris. It is intended for patients who are inadequately controlled by or are intolerant to first-line anti-anginal therapies.

---

Contraindications (Who Cannot Use)

Use of Trimetazidine is contraindicated in several specific groups due to safety concerns:

• Hypersensitivity: Patients with a known allergy to trimetazidine or any of the product's excipients.
• Movement Disorders: Individuals with Parkinson's disease, Parkinsonian symptoms (such as tremors or rigid posture), restless legs syndrome, or other related movement disorders. The drug can cause or worsen these symptoms.
• Severe Renal Impairment: Patients with severe kidney problems (creatinine clearance < 30 mL/min).

Precautions (Use with Caution)

• Moderate Renal Impairment and Elderly Patients (over 75 years old) may require a dose adjustment due to increased drug exposure.
• The medication is not recommended for use in children and adolescents under 18 years old, or during pregnancy and breastfeeding due to insufficient data on safety and efficacy in these populations.

Interaction Map: Interactions with other medicines and products — official regulatory information for Предуктал

Interaction scope

Property	Official Regulatory Statement
Medicinal product categories with documented interactions	None identified.
Specific interacting medicines (if explicitly listed)	None. Regulatory texts confirm that no drug-drug interactions have been identified with other medicinal products.
Mechanistic basis of interactions (only if stated in label)	Not documented. The drug’s elimination is primarily via the kidneys; regulatory data does not specify any clinically relevant metabolic (e.g., CYP-mediated) or transporter-mediated interaction mechanisms.
Timing-based interaction rules (if applicable)	Food: The official label instructs that the modified-release tablet should be administered during meals.
Population-specific interaction notes (if applicable)	Increased plasma exposure is officially observed in the elderly (over 75 years old) and patients with moderate renal impairment (creatinine clearance 30-60 mL/min).
Interaction-related restrictions	No formal contraindications with other medicines are listed due to interaction risk. Restrictions involve adjusting the administration of the medicine based on the patient's renal function.

Interaction classifications (high-level)

Property	Official Regulatory Statement
Interaction severity classification (as defined in official documents)	Not classified, due to the regulatory finding that no drug-drug interactions have been identified.
Regulatory basis	European Medicines Agency (EMA) Summary of Product Characteristics and corresponding national health authority labels.
Interaction-context constraints (as defined in official documents)	Administration must be adjusted in populations where reduced clearance leads to officially increased plasma exposure.

Resulting interaction structure

Official interaction statements:

• No drug interactions have been identified in regulatory documentation with other medicinal products.
• The pharmacokinetics of the modified-release formulation are not influenced by meals.
• Trimetazidine plasma exposure is officially noted to be increased in elderly patients and those with moderate renal impairment.

Connection to the overall interaction profile (4 sentences): The regulatory profile is characterized by the documented absence of identified drug-drug interactions, including those related to common metabolic or transporter pathways. This finding forms the primary interaction statement in official labeling. The main official constraint noted is a population-based pharmacokinetic restriction, where reduced renal clearance in the elderly and in patients with moderate renal impairment leads to an officially observed increase in Trimetazidine exposure.

Предуктал (Trimetazidine) functions as a metabolic anti-ischemic agent by modulating myocardial energy substrate utilization. Its primary mechanism involves the selective inhibition of the long-chain 3-ketoacyl-CoA thiolase (3-KAT) enzyme. This mitochondrial enzyme is essential for the final step of fatty acid beta-oxidation.

Inhibition of 3-KAT effectively reduces the cellular rate of fatty acid oxidation, resulting in a metabolic shift that favors the oxidation of glucose as the primary energy substrate. Glucose oxidation requires less oxygen per mole of ATP generated compared to fatty acid oxidation. This change in substrate utilization increases the overall oxygen efficiency of the cell's energy production and contributes to the preservation of cellular ATP levels during conditions of reduced oxygen supply (hypoxia).

Trimetazidine is administered exclusively via the oral route for its intended use as an add-on therapy. The specific dosing schedule is dependent on the pharmaceutical formulation utilized.

The standard adult dosing regimen for the modified-release 35 mg tablet is one tablet twice daily, taken with meals in the morning and evening, resulting in a total daily dose of 70 mg. For the conventional 20 mg tablet or oral solution, the dosing requires administration three times a day. The modified-release tablets must be swallowed whole to preserve their extended-release profile and must not be crushed, broken, or chewed.

Administration is contingent on the presence of food, as the medicine must be consumed during meals. If a dose is forgotten, the instruction is to resume treatment normally at the next scheduled time; a double dose should not be taken to compensate for the missed one.

Population adjustments are required for certain patient groups. For adult patients diagnosed with moderate renal impairment (creatinine clearance between 30 and 60 mL/min), the dose of the 35 mg modified-release tablet is reduced to one tablet once daily, taken with breakfast. The ongoing benefit of treatment is assessed after three months of use, and the drug is discontinued if a positive response is not observed. The safety and effectiveness of this medicine have not been established for the pediatric population under 18 years of age.

Research Evidence Overview for Предуктал (Trimetazidine)

The research base for Trimetazidine was studied for its classification as a metabolic agent for cardiology drug classification. The available evidence is derived primarily from Randomized Controlled Trials (RCTs), where the medicine was evaluated in specific patient groups under controlled conditions. The studies were often conducted either compared to an inactive placebo or when the agent was added to existing standard treatments. This overview describes the research landscape, the types of outcomes that have been monitored, and the areas where evidence remains limited or where data are still emerging.

---

Evidence for Use in Stable Angina Pectoris

Trimetazidine was studied for adult patients with stable angina pectoris, a condition characterized by chest discomfort often triggered by physical activity. Research explored patient groups whose symptoms were evaluated when the agent was added to their existing standard anti-anginal medications, particularly those whose symptoms were not fully controlled by or who reported an intolerance to these treatments. Short-term clinical trials typically research examined outcomes related to outcomes related to physical discomfort and outcomes reflecting daily functioning.

These studies monitored measurements like the frequency of weekly angina episodes reported by patients and the number of short-acting nitrate medications recorded as used, to track the frequency of nitrate use. Objective measures were evaluated in exercise tests, where researchers explored measures such as the total time spent exercising before symptoms started.

---

Evaluation of Short-Term vs. Long-Term Outcomes

A substantial portion of the evidence for Trimetazidine was studied for short-term effects, with many core evaluation trials focusing on periods of 8 to 12 weeks. This research provides insight into short-term changes in symptom patterns and functional measures. Research on long-term outcomes, such as the frequency of major cardiovascular events (like heart attack or cardiovascular death), is not fully established.

Some larger, extended studies research examined these hard endpoints, with follow-up periods extending up to approximately 4 years. However, the findings related to these long-term hard outcomes were mixed across different studies, and the certainty regarding any long-term effects remains low.

---

Research in Specific Patient Populations

Clinical trials research examined outcomes in various subgroups of adult patients with stable angina. One such subgroup was evaluated in studies including patients who also had Type 2 Diabetes Mellitus (T2DM). The results apply only to the populations studied and data for certain other groups, such as children or women who are pregnant, remain insufficient.

Key Studies & References

1. Summary of Product Characteristics – Trimetazidine Dihydrochloride (HPRA/National Authority)
2. WHO Anatomical Therapeutic Chemical (ATC) Classification System: Trimetazidine
3. Trimetazidine in Stable Angina: Review of Randomized Controlled Trials on Exercise Parameters and Hard Outcomes (Long-term Data)

Common questions about Предуктал (FAQ)

Q: Can I drink alcohol while taking this medication?

Official regulatory documents have not identified any specific drug interactions between the active substance (trime​ta​zidine) and other medicinal products. While no direct interaction with alcohol is typically stated on the label, a healthcare professional can provide guidance on alcohol consumption, which is a general medical precaution.

Q: Is it safe to breastfeed while on this medication?

According to the official product information, it is unknown whether trime​zidine is passed into human milk. Official guidelines state that a risk to the newborn or infant cannot be excluded. Therefore, the medicine is described as not being used during breast-feeding.

Q: What are the symptoms of an overdose?

Experience with overdose is limited, but official documents indicate that symptoms may include low blood pressure, which is medically known as hypotension, and a sensation of facial flushing. In the event of a suspected overdose, it is essential to contact emergency medical services.

Q: Does this drug affect lab test results (e.g., blood sugar, cholesterol)?

Regulatory documents do not specifically list effects on common lab test results like blood sugar or cholesterol. However, rare adverse effects such as blood disorders (like agranulocytosis, a severe drop in white blood cell count) and liver disorders (hepatitis) have been noted in post-marketing data. These conditions would be detectable through specialized laboratory testing.

Q: Do I need to taper off or stop this medication slowly?

Specific instructions for gradually reducing the dose (tapering) are not provided for routine discontinuation. However, regulatory information indicates that the definitive withdrawal of the medicine is appropriate if movement disorders, such as symptoms resembling Parkinson's disease, occur. The majority of patients recover within 4 months after discontinuing the medicine.

Q: What is the commercial status of this drug (e.g., brand name, generic)?

Trime​zidine is marketed under a variety of different trade names globally, including Vastarel. Official regulatory reviews confirm that medicines containing the active substance are available under multiple different invented and generic names.

Q: Does this medicine contain gluten or lactose?

Information on excipients (inactive ingredients) is provided in the official product information. For specific modified-release formulations of the drug (such as Vastarel MR 35 mg), lactose is listed as an excipient. Information regarding gluten is generally not provided in regulatory documents.

Q: Is this medicine approved for the treatment of Meniere's disease or vertigo?

According to official regulatory bodies, trime​zidine is currently indicated only as an add-on treatment for the symptoms of stable angina pectoris. Its use for other conditions is not supported by current regulatory indications.

Q: Does this medicine affect heart rhythm?

Studies and official information indicate that the anti-ischemic effects of this drug are achieved without concomitant haemodynamic effects. This means that the drug does not typically lead to changes in heart rate, heart rhythm, or blood pressure.

Q: How long does it take for the drug to start working?

Clinical studies indicated improvements in physical function measures and a reduction of angina symptoms after 8 to 12 weeks of use. This information is based on the data provided in the official product documentation.

Q: Is there a maximum time I can take this drug?

The official product information does not state an absolute maximum time for use. However, regulatory guidelines mandate that the patient's benefit from the treatment must be formally assessed after the first three months of use. The medicine is described as being discontinued if a positive response is not observed after this period.

Q: Are there any foods I should avoid while on this drug?

The official Interaction Map states that no drug interactions with food have been identified. The main instruction concerning food is that the modified-release tablet should be taken during meals.

Q: Is a generic version of the drug available?

Yes, regulatory overview documents confirm that the active substance, trime​zidine, is marketed under various trade names and includes generic versions.

Q: Is this a preventative medicine?

Official warnings clarify the role of the medicine in treatment. The drug is described as not being a curative treatment for angina attacks. Furthermore, it is not indicated as an initial, primary treatment for unstable angina or for a heart attack (myocardial infarction).

Q: Does this medicine have a black box warning in the US?

The U.S. Food and Drug Administration (FDA) has not approved trime​zidine for use in the United States. Therefore, it does not carry a Black Box Warning within the FDA regulatory system.

How to Store and Dispose of Предуктал

Official regulatory documents strictly define the storage and disposal requirements for Предуктал (Trimetazidine) modified-release tablets to ensure product integrity and public safety.

---

Storage Requirements

Condition	Regulatory Mandate
Temperature	Do not store above mathbf30 C
Container	Keep the medicine in the original container
Child Safety	Keep strictly out of the sight and reach of children

---

Disposal Instructions

Unused or expired Предуктал must be disposed of properly to protect the environment. Regulatory instructions state that the medicine should not be disposed of via household waste or wastewater. Consult a pharmacist for guidance, as disposal must be in accordance with local requirements for pharmaceutical waste.